99 related articles for article (PubMed ID: 10509009)
1. Decreased expression of the Fas ligand on peripheral blood mononuclear cells and undetectable levels of soluble Fas ligand in the serum of patients with aplastic anemia and myelodysplastic syndrome.
Shinohara K; Takahahi T; Nawata R; Oeda E
Am J Hematol; 1999 Oct; 62(2):124-5. PubMed ID: 10509009
[No Abstract] [Full Text] [Related]
2. Fas/Fas-ligand expressions in peripheral-blood mononuclear cells of patients with myelodysplastic syndromes.
Hirano T; Hiratsuka N; Iwahori T; Oka K; Wakasugi K
Res Commun Mol Pathol Pharmacol; 2003; 113-114():315-28. PubMed ID: 15686130
[TBL] [Abstract][Full Text] [Related]
3. [The expression of Fas antigen and plasma levels of sFas and sFasL in patients with aplastic anemia].
Ren C; Zhang M; Xu C; Zhang T
Zhonghua Xue Ye Xue Za Zhi; 2000 Apr; 21(4):198-200. PubMed ID: 11876982
[TBL] [Abstract][Full Text] [Related]
4. Leukocyte alkaline phosphatase score correlation with bone marrow blast percentage in myelodysplastic syndrome.
Lipshitz J; Limaye S; Patel D
Acta Haematol; 2010; 124(3):179-81. PubMed ID: 20962518
[No Abstract] [Full Text] [Related]
5. Elevated plasma level of differentiation inhibitory factor nm23-H1 protein correlates with risk factors for myelodysplastic syndrome.
Ito Y; Okabe-Kado J; Honma Y; Iwase O; Shimamoto T; Ohyashiki JH; Ohyashiki K
Leukemia; 2002 Feb; 16(2):165-9. PubMed ID: 11840281
[TBL] [Abstract][Full Text] [Related]
6. [Expression of Fas, FasL and Bcl-2 and apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome].
Zhang Z; Xie J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):274-7. PubMed ID: 12844412
[TBL] [Abstract][Full Text] [Related]
7. Definition of CD 11a, b, c, and CD 18 glycoproteins on chemotactically deficient granulocyte membranes in patients affected by myeloid disorders.
Ricevuti G; Mazzone A; Notario A
Acta Haematol; 1989; 81(3):126-30. PubMed ID: 2565640
[TBL] [Abstract][Full Text] [Related]
8. Classification of the myelodysplastic syndromes.
Bennett JM
Clin Haematol; 1986 Nov; 15(4):909-23. PubMed ID: 3471370
[No Abstract] [Full Text] [Related]
9. Responsiveness of bone marrow erythropoietic stem cells (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) in vitro in aplastic anemia and myelodysplastic syndrome.
Aoki I; Higashi K; Homori M; Chikazawa H; Ishikawa K
Am J Hematol; 1990 Sep; 35(1):6-12. PubMed ID: 2389770
[TBL] [Abstract][Full Text] [Related]
10. Immunohematological findings in myelodysplastic syndrome.
Novaretti MC; Sopelete CR; Velloso ER; Rosa MF; Dorlhiac-Llacer PE; Chamone DA
Acta Haematol; 2001; 105(1):1-6. PubMed ID: 11340246
[TBL] [Abstract][Full Text] [Related]
11. [The comparative characteristics of the clinico-hematological indices in patients with different forms of myelodysplasias].
Pesotskaia LA
Lik Sprava; 1997; (2):59-62. PubMed ID: 9333486
[TBL] [Abstract][Full Text] [Related]
12. [Clinical, hematologic and developmental characteristics of myelodysplastic syndromes. Study of a group of patients with a long-term follow-up].
Di Giovanni S; Giallonardo P; Costa MP; Carducci P
Recenti Prog Med; 1987 Feb; 78(2):63-8. PubMed ID: 3473582
[No Abstract] [Full Text] [Related]
13. Marked decreases of total and immature reticulocytes in myelodysplastic syndrome among patients with pancytopenia.
Kabutomori O; Kanakura Y; Iwatani Y
Acta Haematol; 2003; 109(4):212-3. PubMed ID: 12853698
[No Abstract] [Full Text] [Related]
14. [Diagnosis, course and outcome of myelodysplasias].
Riauzova LIu; Soloveĭ DIa; Iavorkovskiĭ LI; Iavorkovskiĭ LL; Grinberg LIa
Gematol Transfuziol; 1988 Aug; 33(8):19-23. PubMed ID: 3192050
[No Abstract] [Full Text] [Related]
15. Detection of CD55- and CD59-deficient granulocytic populations in patients with myelodysplastic syndrome.
Kaiafa G; Papadopoulos A; Ntaios G; Saouli Z; Savopoulos C; Tsesmeli N; Kontoninas Z; Chatzinikolaou A; Tsavdaridou V; Klonizakis I; Hatzitolios A
Ann Hematol; 2008 Apr; 87(4):257-62. PubMed ID: 18158579
[TBL] [Abstract][Full Text] [Related]
16. Detection of soluble IL-2 receptor in the serum of patients with myelodysplastic syndromes: induction under therapy with GM-CSF.
Zwierzina H; Herold M; Schöllenberger S; Geissler D; Schmalzl F
Br J Haematol; 1991 Nov; 79(3):438-43. PubMed ID: 1751371
[TBL] [Abstract][Full Text] [Related]
17. [The morphofunctional characteristics of the bone marrow erythroid cells in some forms of the myelodysplastic syndrome].
Sarycheva TG; Tsvetaeva NV; Kozinets GI
Ter Arkh; 1993; 65(7):52-4. PubMed ID: 8211781
[TBL] [Abstract][Full Text] [Related]
18. Defective cytotoxicity of T lymphocytes in myelodysplastic syndrome.
Cukrová V; Neuwirtová R; Dolezalová L; Belicková M; Bartůnková J; Jonásová A; Cermák J; Homolková H; Malíková I
Exp Hematol; 2009 Mar; 37(3):386-94. PubMed ID: 19136196
[TBL] [Abstract][Full Text] [Related]
19. Elevation of the serum Fas ligand in patients with hemophagocytic syndrome and Diamond-Blackfan anemia.
Hasegawa D; Kojima S; Tatsumi E; Hayakawa A; Kosaka Y; Nakamura H; Sako M; Osugi Y; Nagata S; Sano K
Blood; 1998 Apr; 91(8):2793-9. PubMed ID: 9531589
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotype of myeloid granulocytes: a pilot study for distinguishing myelodysplastic syndrome and aplastic anemia by flow cytometry.
Huang M; Li J; Zhao G; Sui X; Zhao X; Xu H
Int J Lab Hematol; 2010 Jun; 32(3):275-81. PubMed ID: 19968721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
